ADC Therapeutics (ADCT) Net Equity Issued and Repurchased (2024 - 2026)

ADC Therapeutics (ADCT) posted Net Equity Issued and Repurchased of -$20000.0 for Q1 2026, down 100.05% sequentially from $43.5 million in Q4 2025.

ADC Therapeutics (ADCT) Net Equity Issued and Repurchased (2024 - 2026) Analysis & Trends

ADC Therapeutics has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at -$20000.0 in Q1 2026.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to -$20000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.7 million (up 7180.9% YoY) and the FY2025 annual result came in at $86.3 million, up 42.6% from the prior year.
Net Equity Issued and Repurchased retreated to -$20000.0 in Q1 2026 per ADCT's latest filing, from $43.5 million in the prior quarter.
Over five years, Net Equity Issued and Repurchased peaked at $43.5 million in Q4 2025 and troughed at -$1.2 million in Q3 2024.
A 3-year average of $21.4 million and a median of $21.6 million in 2025 frame the typical range for Net Equity Issued and Repurchased.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	49.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	ADC Therapeutics	154.55 Mn	-64.56 Mn	17.14 Mn	-

Download Data